Galapagos and Gilead finalize a framework agreement tied to Ouro’s acquisition, advancing gamgertamig, a BCMAxCD3 T-cell engager for autoimmune diseases.
Written By: Vennela Reddy, BPharm
Reviewed By: Pharmacally Editorial Team
Galapagos NV and Gilead Sciences have formalized a binding framework agreement linked to Gilead’s planned acquisition of Ouro Medicines, bringing the investigational T-cell engager Gamgertamig (OM336) into a structured global development and commercialization pathway.
The agreement builds on Gilead’s previously announced $1.675 billion acquisition of Ouro, with up to $500 million in milestone payments. It defines Galapagos’ participation, access to key assets, and co-development of gamgertamig, a clinical-stage therapy targeting autoantibody-driven autoimmune diseases.
Gamgertamig is a BCMAxCD3 bispecific T-cell engager that redirects T cells to eliminate pathogenic plasma cells and B cells. In Phase 1/2 studies, it has shown rapid, deep cell depletion with a differentiated safety profile after a single treatment cycle, including in autoimmune hemolytic anemia and immune thrombocytopenia. The program has received Fast Track and Orphan Drug designations from the U.S. FDA and is expected to enter registrational studies as early as 2027.
Under the framework, Galapagos will fund 50% of the upfront acquisition cost and future milestones. It will lead early-stage development prior to registrational trials, while later-stage costs will be shared equally with Gilead. Gilead will lead global commercialization outside territories held by Keymed Biosciences, paying tiered royalties of 20–23% on net sales.
The agreement grants Galapagos licenses to key intellectual property from Ouro’s pipeline, including gamgertamig and additional multispecific T-cell engager programs. It will also acquire substantially all of Ouro’s operational assets, including facilities and personnel, adding an integrated R&D platform.
Commenting on the agreement, Henry Gosebruch said it marks a key step in the company’s transformation, adding a high-potential asset while preserving financial flexibility, enabling further strategic deals and up to $150 million in potential shareholder returns.
Galapagos retains strategic flexibility through a waiver under its 2019 collaboration with Gilead, allowing deployment of at least $500 million independently, including up to $150 million for potential shareholder returns.
Beyond gamgertamig, Galapagos will gain access to three preclinical autoimmune programs from Ouro, with Gilead retaining opt-in rights after proof-of-concept, supporting a long-term collaboration.
Reference
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases, 31 March 2026, Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases – Galapagos
About the Writer
Vennela Reddy, B.Pharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.